Clinical Trial: Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis

U.S., June 23 -- ClinicalTrials.gov registry received information related to the study (NCT07660835) titled 'Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis' on May 28.

Brief Summary: The primary objective of the study is to assess the pharmacokinetics (PK) and safety of nemolizumab in pediatric participants (aged 6-23 months) with moderate-to-severe atopic dermatitis (AD) who are not adequately controlled with topical treatments.

Study Start Date: June 30

Study Type: INTERVENTIONAL

Condition: Moderate-to-Severe Atopic Dermatitis

Intervention: DRUG: Nemolizumab

A lyophilized powder for solution for SC injection.

Recruitment Status: NOT_YET_RECRUITING...